Recent News

• 03.26.2026 - Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
• 03.05.2026 - Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
• 02.26.2026 - Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• 02.23.2026 - Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
• 02.19.2026 - Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

Recent Filings

• 03.26.2026 - 8-K Current report
• 03.26.2026 - EX-99.1 EX-99.1
• 03.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2026 - EX-99.1 EX-99.1
• 02.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.26.2026 - 8-K Current report
• 02.12.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.11.2026 - 4 Statement of changes in beneficial ownership of securities